Matthew Blischak
Directeur Général chez FINCH THERAPEUTICS GROUP, INC.
Fortune : - $ au 30/04/2024
Provenance du réseau au premier degré de Matthew Blischak
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY.
18
| Subsidiary | Pharmaceuticals: Major | 18 |
| Unknown | 10 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Matthew Blischak via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| SIO GENE THERAPIES INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director of Finance/CFO Chairman Chief Executive Officer | |
Axovant Sciences, Inc.
 Axovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sio Gene Therapies, Inc., Axovant Sciences, Inc. is a company that manufactures and distributes pharmaceutical products. The company is based in New York, NY. | Pharmaceuticals: Major | Director of Finance/CFO Chairman Chief Executive Officer General Counsel | |
| ARBUTUS BIOPHARMA CORPORATION | Pharmaceuticals: Major | Director/Board Member Chairman Chairman Director/Board Member | |
Altavant Sciences, Inc.
 Altavant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Altavant Sciences, Inc. is a clinical stage biopharmaceutical company, which provides therapies that treat respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension (PAH). The company is headquartered in Cary, NC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| MYOVANT SCIENCES LTD. | Biotechnology | Chairman Director/Board Member Chairman | |
| IMMUNOVANT, INC. | Biotechnology | Director/Board Member Director/Board Member Chairman | |
Shumway Capital Management LLC
 Shumway Capital Management LLC Investment ManagersFinance Shumway Capital Management LLC (Shumway Capital) is a private equity and venture capital firm founded in 2001 by Chris Shumway. The firm is headquartered in Greenwich, Connecticut. | Investment Managers | Founder Private Equity Investor | |
| UNC School of Medicine | College/University | Doctorate Degree Doctorate Degree | |
Sumitovant Biopharma, Inc.
 Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| Yale Law School | College/University | Graduate Degree Graduate Degree | |
Arbutus Biopharma, Inc.
 Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Biotechnology | Director/Board Member Director/Board Member | |
SCP III LP
 SCP III LP Investment ManagersFinance Founded by Chris Shumway in 2002, SCP III LP, dba Shumway Capital Investments, is a family office and growth equity investment firm located in Greenwich, Connecticut. | Investment Managers | Chief Executive Officer Director of Research - Equity | |
| Alyvant, Inc. | President General Counsel | ||
Immunovant Sciences Ltd.
 Immunovant Sciences Ltd. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Immunovant Sciences Ltd. develops restorative therapies for autoimmune diseases. The company is based in Hamilton, Bermuda. Immunovant Sciences was acquired by Health Sciences Acquisitions Corp. from Roivant Sciences Ltd. on December 19, 2019 for $863.06 million. | Biotechnology | Director/Board Member Chairman | |
Dermavant Sciences Ltd.
 Dermavant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Dermavant Sciences Ltd. is a clinical-stage biopharmaceutical company which focuses on developing and commercializing therapeutics in medical dermatology. The company is developing a pipeline of therapies in medical dermatology and is currently advancing development programs for five product candidates which targets specific unmet needs in two of the immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis and acne. The company was founded on September 28, 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| Harvard College | College/University | Undergraduate Degree Undergraduate Degree | |
| Harvard Law School | College/University | Graduate Degree Graduate Degree | |
| The Wharton School of the University of Pennsylvania | College/University | Undergraduate Degree Undergraduate Degree | |
| UROVANT SCIENCES LTD. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Dermavant Sciences, Inc.
 Dermavant Sciences, Inc. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Dermavant Sciences, Inc. develops biological products. The company is based in Raleigh, NC. Todd Zavodnick has been the CEO of the company since 2018. | Biotechnology | Director/Board Member Chairman | |
| ROIVANT SCIENCES LTD. | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO | |
| AXSOME THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Pharmaceuticals: Other | Public Communications Contact Corporate Officer/Principal | |
| Princeton University | College/University | Undergraduate Degree Undergraduate Degree | |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| The University of Chicago | College/University | Director/Board Member Doctorate Degree | |
Genevant Sciences Corp.
 Genevant Sciences Corp. Pharmaceuticals: MajorHealth Technology Part of Roivant Sciences Ltd., Genevant Sciences Corp. operates as a Canadian biopharmaceutical company. The company is based in Burnaby, Canada. The CEO of the company is Bo Rode Hansen. | Pharmaceuticals: Major | Chairman | |
Point32health Services, Inc.
 Point32health Services, Inc. Life/Health InsuranceFinance Tufts Associated Health Plans, Inc. provides healthcare plans. It offers health care coverage options to individuals and employer groups. The firm also offers choice tiered network option plan and Steward Community Choice, a community-based plan, developed in conjunction with Steward Health Care System. The company was founded by Morton A. Madoff in 1979 and is headquartered in Watertown, MA. | Life/Health Insurance | Director/Board Member | |
QVT Financial LP
 QVT Financial LP Investment ManagersFinance QVT Financial LP is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded in 2003 by Daniel Gold. QVT Financial provides administrative and/or investment management services to private funds including US limited partnerships, non-US limited partnerships and non-US Corporation. | Investment Managers | Analyst-Equity | |
| The University of North Carolina at Chapel Hill | College/University | Undergraduate Degree | |
Campus Venture Network, Inc.
 Campus Venture Network, Inc. Internet Software/ServicesTechnology Services Campus Venture Network, Inc. operates a website. The private company is based in Cary, NC. The company was founded by S. Travis May, Vivek Ramaswamy. | Internet Software/Services | Founder | |
Strive Asset Management LLC
 Strive Asset Management LLC Investment ManagersFinance Part of Strive Enterprises, Inc., Strive Asset Management LLC is an asset management firm based in Dublin, OH. The company's mission is to restore the voices of everyday citizens in the American economy by leading companies to focus on excellence over politics. Strive will compete directly with the world's largest asset managers by launching index funds that advance excellence capitalism across corporate America. The company was founded by Vivek Ramaswamy and Anson Frericks in 2022, and Matthew Cole has been the CEO of the company since 2022. | Investment Managers | Founder | |
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Pharmaceuticals: Major | Chairman | |
Xoc Pharmaceuticals, Inc.
 Xoc Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Xoc Pharmaceuticals, Inc. operates as Biopharmaceutical Company. It focuses on the development of innovative therapeutics. The company was founded by Scott W. Borland, Miguel Guzman and Lisa Borland and is headquartered in Los Gatos, CA. | Miscellaneous Commercial Services | Director/Board Member | |
New Enterprise Associates LLC
 New Enterprise Associates LLC Investment ManagersFinance New Enterprise Associates LLC is an alternative investment manager. The private company is based in Timonium, MD. The company was founded in 1978 by Chuck Newhall, C. Richard Kramlich. | Investment Managers | Corporate Officer/Principal | |
NEA Management Co. LLC
 NEA Management Co. LLC Investment ManagersFinance New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor | |
| NEXIMMUNE, INC. | Pharmaceuticals: Major | Director/Board Member | |
DC Brau Brewing LLC
 DC Brau Brewing LLC Beverages: AlcoholicConsumer Non-Durables DC Brau Brewing LLC manufactures and distributes beer. The company was founded by Jeffrey Hancock and Brandon Skall in 2009 and is headquartered in Washington, DC. | Beverages: Alcoholic | Director/Board Member | |
UTILITY therapeutics Ltd.
 UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Pharmaceuticals: Generic | Chairman | |
| Goizueta Business School-Emory | College/University | Masters Business Admin | |
| Rollins School of Public Health | College/University | Graduate Degree | |
| IN8BIO, INC. | Biotechnology | Chairman | |
| Sompharmaceuticals SA | Director/Board Member | ||
| Helene Fuld College of Nursing | College/University | Director/Board Member | |
Bit Bio Ltd.
 Bit Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Bit Bio Ltd. engages in research and experimental development on natural sciences and engineering. Its products are human-induced skeletal myocytes and glutamatergic neurons. The company was founded by Mark Kotter in 2016 and is headquartered in Cambridge, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 41 |
| Royaume-Uni | 7 |
| Bermudes | 2 |
| Canada | 2 |
| Islande | 2 |
Sectorielle
| Health Technology | 25 |
| Consumer Services | 13 |
| Finance | 9 |
| Commercial Services | 3 |
| Technology Services | 2 |
Opérationnelle
| Director/Board Member | 115 |
| Corporate Officer/Principal | 47 |
| Chief Executive Officer | 32 |
| Chairman | 31 |
| Independent Dir/Board Member | 30 |
Relations les plus connectées
| Insiders | |
|---|---|
| Myrtle Potter | 41 |
| Frank Torti | 35 |
| Alan Roemer | 21 |
| Jeffery Smisek | 18 |
| Roger Jeffs | 18 |
| Andrew Fromkin | 16 |
| Vivek Ramaswamy | 14 |
| David S. Moore | 13 |
| Lance Thibault | 11 |
| Gillian Cannon | 11 |
| William T. Symonds | 11 |
| Chris Shumway | 10 |
| Susan Graf | 9 |
| Tiago Girão | 9 |
| Domenic Ferrante | 7 |
- Bourse
- Insiders
- Matthew Blischak
- Connexions Sociétés